Xgeva approved for rare, non-malignant tumor

June 13, 2013

(HealthDay)—Xgeva (denosumab) has been approved by the U.S. Food and Drug Administration to treat giant cell tumor of the bone (GCTB), a rare tumor that's most often non-cancerous.

The tumor usually affects adults between ages 20 and 40, although it may also develop in adolescents, the FDA said Thursday in a news release. It typically doesn't spread, although in rare cases it can become cancerous and travel to the lungs.

As a non-, GCTB destroys bone as it becomes larger, causing pain, fractures and loss of mobility. Xgeva has been approved in cases where the tumor can't be surgically removed, or might lead to a severe outcome such as loss of a limb, the agency said.

Xgeva, approved under the FDA's expedited review program, was evaluated for this use in two clinical trials involving a total of 305 adults and adolescents. Common side effects included joint pain, headache, nausea, fatigue, back pain and extremity pain.

Women of childbearing potential should use "highly effective" contraception while taking Xgeva, since the drug can harm a fetus, the FDA warned.

The drug was first approved in 2010 to prevent fractures when cancer has spread to the bone. It's marketed by , based in Thousand Oaks, Calif.

More information: The FDA has more about this approval.

Related Stories

Generic boniva approved for osteoporosis

March 19, 2012

(HealthDay) -- The first generic versions of the once-monthly osteoporosis drug Boniva (ibandronate) have been approved by the U.S. Food and Drug Administration.

Cometriq approved for rare thyroid cancer

November 29, 2012

(HealthDay)—Cometriq (cabozantinib) has been approved by the U.S. Food and Drug Administration to treat modullary thyroid cancer that has spread to other parts of the body, the agency said Thursday.

Iclusig approved for rare leukemias

December 16, 2012

(HealthDay)—Iclusig (ponatinib) has been approved by the U.S. Food and Drug Administration to treat two rare forms of leukemia..

Lymphoseek approved to help locate lymph nodes

March 13, 2013

(HealthDay)—The injected imaging drug Lymphoseek (technetium Tc 99m tilmanocept) has been approved by the U.S. Food and Drug Administration to help surgeons locate the lymph nodes among people with breast cancer or melanoma.

Dotarem approved for nervous system MRIs

March 21, 2013

(HealthDay)—Dotarem (gadoterate meglumine) has been approved by the U.S. Food and Drug Administration as a contrast agent for use in MRIs of the brain, spine and other parts of the central nervous system.

Simponi approved for ulcerative colitis

May 15, 2013

(HealthDay)—Simponi (golimumab) injection has been approved by the U.S. Food and Drug Administration to treat adults with moderate-to-severe ulcerative colitis.

Recommended for you

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.